Cell loss no greater with femtosecond lasers

Article

Penetrating keratoplasty (PK) with a femtosecond laser offers good surgical results and endothelial cell loss numbers similar to those found for PK using standard trephines.

Penetrating keratoplasty (PK) with a femtosecond laser offers good surgical results and endothelial cell loss numbers similar to those found for PK using standard trephines, according to Mike Holzer and co-workers at the International Vision Correction Research Centre, Heidelberg University, Germany.

Eleven eyes of 10 subjects underwent uneventful PK with a femtosecond laser. Endothelial cell counts were taken on the corneal donor buttons prior to surgery and measurements were taken at 12 and 24 months postoperatively using a specular microscope.

Preoperative cell counts ranged between 2,300 and 2,750 cells/mm2. At 24 months postoperatively, all corneal transplants were clear and visual acuity had improved from preoperative levels. The postoperative cell counts ranged between 1,350 and 2,100 cells/mm2, whilst the median cell loss was recorded as 35.9%.

It was concluded that cell loss is similar in patients undergoing PK with a femtosecond laser and in those undergoing treatment using conventional trephines.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.